E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis |
|
E.1.1.1 | Medical condition in easily understood language |
Effect of dapagliflozin treatment on the switch between carbohydrate and lipid oxidation during the night |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to examine the effects of dapagliflozin on nocturnal substrate oxidation in overweight or obese subjects with disrupted glucose homeostasis but without T2D. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to examine if dapagliflozin changes as compared to placebo: - hepatic glycogen content in the morning and evening - 24h glucose, protein or fat oxidation - 24h plasma glucose, NEFA and total amino acid levels, incl. BCAA levels - 24h plasma insulin and glucagon profiles - muscle mitochondrial function - intrahepatic lipid content and composition - intramyocelluar lipid content and composition, including acetylcarnitine levels in the overnight fasted and late afternoon - muscle glycogen content in the overnight fasted and late afternoon - systolic and diastolic blood pressure in the overnight fasted and late afternoon |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of signed and dated informed consent prior to any study specific procedures. 2. Males aged ≥ 40 and ≤ 75 years and post-menopausal women (defined as at least 1 year post cessation of menses) aged ≥ 50 and ≤ 75 years 3. Body mass index (BMI) ≥ 27 and ≤ 38 kg/m2. 4. Sedentary lifestyle (not more than 2 hours of vigorous exercise per week). 5. Stable dietary habits. 6. Impaired glucose homeostasis based on one or a combination of the following criteria: - Impaired Glucose Tolerance (IGT): plasma glucose values ≥ 7.8 mmol/l and ≤ 11.1 mmol/l 120 minutes after consumption of the glucose drink during the 2h, 3-point OGTT. - Impaired Fasting Glucose (IFG): fasting plasma glucose ≥ 6.1 mmol/l and ≤ 6.9 mmol/l. - Insulin Resistance: glucose clearance rate ≤ 360 ml/kg/min, as calculated by Oral Glucose Insulin Sensitivity 120 (OGIS120) model based on the 2h, 3-point OGTT. - HbA1c ≥ 5.7% and ≤ 6.4%. |
|
E.4 | Principal exclusion criteria |
1. Clinical diagnosis of Type 1 or 2 Diabetes Mellitus. 2. Active cardiovascular disease 3. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. 4. Regular smoking and other regular nicotine use. 5. Anaemia. 6. Uncontrolled hypertension. 7. Clinically significant abnormalities in clinical chemistry or hematology 8. Unstable or rapidly progressing renal disease or estimated Glomeral Filtration Rate (eGFR) <60 mL/min (Cockcroft-Gault formula). 9. Use of anti-coagulant treatment 10. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. 11. Use of loop diuretics. 12. Intake of dietary supplements except multi-vitamins and minerals. 13. Alcohol consumption of > 14 drinks per week for women and > 21 drinks per week for men. 14. Known hypersensitivity to dapagliflozin or any of the excipients of the product. 15. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding. 16. Any contraindication for MRI scanning. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To investigate if Dapagliflozin improves nocturnal substrate oxidation as measured by respiratory quotient (VCO2/VO2) between placebo and active treatment after 2 week double blind treatment. Nocturnal substrate oxidation will be determined during the sleep- period. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |